Corcept Therapeutics is trading at $91.02, up 5.49%, with no verified company-specific announcement explaining the October 28 after-hours move.
- The latest identified company news was its October 27 notice that it will report Q3 results on November 3.
- Positive Phase 2 BELLA results announced October 26 are recent background, but available reporting does not establish them as the direct cause of the rise.
- The broader market was mixed, not a clear same-direction driver.